In the course of evolution, bacteria from the genus Salmonella adapted to survive and multiply in a vertebrate host.
Radio-and chemotherapy of cancer is not fully effective and meta stases remain the major cause of death from cancer. Low selectivity for tumor cells markedly reduces the benefit of these therapies. The mechanism of action based on such biological process as cell proliferation cannot provide cytotoxicity limited to tumor tissue, resulting in devastating side effects. Selective cancer immunotherapy should overcome these drawbacks, with the inhibition of meta stases being the main target.
The history of tumor immunotherapy began over 130 years ago when physicians started to treat cancer patients with microorganisms. The progress in immuno logical para digms on the role of the immune system in cancer progression and development in genetic engineering allowed to rediscover the strategy. Preclinical and clinical studies showed that tumor antigen--targeted therapies alone are not as effective as expected. Limited accessibility of tumor tissue for effector cytotoxic cells, lack of costimulation leading to anergic state and tolerance of T-helper cells, reduced expression of major histocompatibility complex (MHC) molecules on tumor cells and immunosuppresive tumor environment resulted in low effectiveness of immunotherapies based on the stimulation of tumor antigen--specific responses.
1 Numerous strategies have been used to stimulate local immune response and intensify cross-presentation of tumor antigens,
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Therapeutic vaccines based on genetically modified Salmonella: a novel strategy in cancer immunotherapy ic material, which is then expressed by eukaryotic translational apparatus (TAbLE 1) .
Therapeutic bacterial vaccine vector should not trigger strong antibacterial immune response, so that bacteria are not quickly eliminated from the body after repeated administration. Repeated doses may be necessary to achieve full therapeutic effect and will be effective only in the case of their poor immunogenicity. Salmonella fulfills this requirement due to attenuating mutations that minimize systemic inflammatory responses. Moreover, various mutations result in altered tropism toward infected populations of cells and different immunogenicity. 11,12 By introducing different modifications, an adequate balance between attenuation and immunogenicity can be achieved. As for any other vaccination, anticancer therapeutic vaccine should properly polarize the response, in this case -towards cellular immunity. As an intracellular pathogen, Salmonella triggers Th1 cellular immune response; however, further modifications leading to increased polarization towards cellular immunity are needed.
Tumor targeting and tumor growth inhibition were studied in murine tumor models after systemic or local S. typhimurium administration. Bacteria injected intravenously colonize distant solid tumors and meta stases inaccessible by other routes. Alternatively, bacteria are injected into tumor mass or given through oral gavage to treat intestine cancer lesions. Since the latter possibility requires transgenic or orthotopic tumor models, it has been extremely poorly explored. Most of the results come from less demanding transplantable tumor models. The primary objective of both local and systemic administration is to maximize tumor colonization. Local accumulation of bacteria leads to acute inflammation focused at tumor site. Cancer cells are frequently recognized by the immune system as nonself, but the absence of danger signal precludes proper reactivity. The local occurrence of both signals at tumor site is a prerequisite for the induction of effective immunity.
The suspected mode of tumor growth inhibition by S. typhimurium is a combination of direct cytotoxicity towards infected tumor cells and anticancer immunity evoked by acute inflammation. In the course of infection, Salmonella exports effector proteins which inter act with host cells and influence immune response. Salmonella-infected macrophages and epithelial cells undergo apoptosis followed by IL-1β release.
13-15
Cytotoxicity towards cancer cells seems to be a minor component of tumor growth control because of attenuated virulence. Apoptosis of infected cancer cells can trigger antitumor immunity through facilitating tumor antigen cross-presentation. 16, 17 In this process, antigens originating from proteins produced outside professional antigen presenting cells (APC) are processed and presented on MHC class I molecules to cytotoxic T cells (CTL). The antigenic material is acquired by APC via phagocytosis of apoptotic cells. Cross-presentation results in cross-stimulation e.g., cryoablation or administration of in vitro preactivated dendritic cells directly into the tumor. 2,3 As an alternative and supplementation, nonspecific boosting therapies are being developed. An example of such therapy is administration of high doses of cytokines, which, however, causes severe adverse effects.
Bacteria offer unique advantages unavailable to passive therapeutics and superior to other immunotherapeutics. Bacteria are motile, penetrate tumor tissue, and serve as bio factories producing a therapeutic agent. Properly equipped bacteria deliver a local danger signal to the immune system prompting effective antitumor immunity.
Live attenuated Salmonella typhimurium (S. typhimurium) inhibits tumor growth and promotes survival of tumor-bearing mice. Numerous strains were shown to selectively colonize solid tumors in animal models: the amount of bacteria in tumor exceeds 1000 to 10,000 times the number of bacteria in the spleen and liver (organs naturally occupied by Salmonella during systemic infection). As a result, therapeutic action is focused on the tumor and the rest of the body is exposed to moderate side effects. Modern genetic manipulation tools supported by relatively well known genetics and physiology of genus Salmonella allow to introduce sophisticated modifications into bacterial phenotype to improve safety and efficacy. The prevailing laboratory strains used for therapeutic vaccine design are derivatives of S. typhimurium SL14 028, SL7207, and SL1344 lineages. Their genetic material was modified by in vitro selection and genetic engineering in order to: 1) control pathogenicity and 2) enhance antitumor activity. Proper modifications maximize the benefit from features inherent to pathogen and minimize toxicity.
Ability to accumulate in solid tumors as well as a number of other features make S. typhimurium an excellent therapeutic modality. Salmonella invades, survives, and multiplies inside the cells of an infected organism. Therefore, it can serve as a vehicle that delivers a therapeutic cargo to cells in the form of coding DNA (cDNA). Coded genes are expressed either by bacterial or eukaryotic translational apparatus in order to yield an active protein product. There is no need to enclose any preformed drug. Instead, the recipe in the form of genetic material is amplified, preferably after bacteria reach the tumor, to release a therapeutic protein locally within the tumor. To date, supplied cDNA have coded tumor-specific or tumor--associated antigen, prodrug converting enzyme, cytokine, apoptosis-inducing factor, antiangiogenic factor, or regulatory RNA (TAbLE 1) .
4-10 Rational design of the expression system enables to produce a favorable form of protein, which is either transported to bacterial cell surface or secreted outside bacteria. The exact form profoundly affects the outcome of a therapeutic intervention. S. typhimurium has also been used in gene therapy as a vehicle for the delivery of genet-proliferation and IFN-γ release. Skin depigmentation indicated breaking tolerance to tumor--associated self antigens (common with B16).
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Instead of picking up and processing antigens by themselves, dendritic cells can receive peptide antigens through gap junctions from other cells. Saccheri et al. 22 showed that Salmonella-infected melanoma cells restored the ability to form functional gap junctions with DC, resulting in the presentation of transferred antigen.
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The mechanism of S. typhimurium preferential accumulation in solid tumors Numerous strains of S. typhimurium selectively colonize solid subcutaneous tumors and hepatic or pulmonary metastases in mice. 23, 24 Defective meta bolism, chemotaxis, motility, and local immunosuppression account for preferential accumulation of Salmonella in solid tumors. Motile and facultatively anaerobic Salmonella penetrate tumor tissue better than passively diffusing therapeutics, also into necrotic tumor areas distant from the vasculature. 24, 25 The majority of strains are auxotrophic, i.e., dependent on external sources of essential meta bolites (amino acids, aromatic compounds, or purines). For example, chemical mutagenesis, followed by selection for decreased toxicity, increased adherence to cancer cells and enhanced tumor targeting, resulted in S. typhimurium A1-R strain, auxotrophic for leucine and arginine. 26 Hence the explanation of tumor targeting refers to tumor tissue as a source of nutrients highly concentrated in tumors. Chemotaxis is essential (cross-priming) or tolerance (cross-tolerance), depending on the presence of costimulatory signal, which is dependent on APC maturity. 18, 19 The molecules of bacterial origin (pathogen-associated molecular patterns -PAMP) stimulate APC maturation to immunostimulatory phenotype. 19 Mature APC produce inter leukin (IL)-12, tumor necrosis factor α (TNF-α), IL-1β, IL-6, inter feron (IFN) α and β, activating T cells and IL-12 is crucial for the polarization of the immune response towards Th1 cellular immunity. Therefore, a danger signal promotes costimulation and effective CTL response. Salmonella outer membrane protein A (OmpA) induces the maturation of bone marrow derived dendritic cells. 20 Taken together, the application of therapeutic Salmonella strain provides both increased amount of apoptotic cancer cells and immune-stimulating signals.
Cross-presentation of tumor-associated antigen and CTL stimulation were detected after local Salmonella administration. Mice were bearing subcutaneous melanoma B16-OVA tumors, expressing a model antigen, i.e., ovalbumin (OVA), and S. typhimurium was injected into tumors. Production of anti -inflammatory cytokines (IL-10, IL-13, IL-4 and transforming growth factor β) in tumor--draining lymph nodes decreased to a similar level as in non-tumor -bearing mice; proinflammatory IL-1β and IFN-γ were elevated. Dendritic cells isolated from tumor-draining lymph nodes from mice that received bacteria had a more activated phenotype, cross-presented MHC class I -restricted OVA epitope, and induced lymphocyte Fifteen women with advanced cervical cancer were treated with Lovaxin C, which produces E7 antigen of HPV-16 origin and targets cervical carcinoma. The overall survival of 6 patients was improved and in 4 of 13 evaluated patients a reduction of tumors was observed. The anaerobic Clostridium novyi NT (strain devoid of major systemic toxin gene) spores are predisposed to target hypoxic areas of tumors. The extent of toxicity is correlated with tumor size. Toxicity of this inter vention results from spore germination and increases with the progression of hemo rrhagic necrosis within the tumor. Spores are extremely sensitive to oxygen and do not germinate in aerobic conditions; therefore, well-oxygenated areas of tumors are not affected directly by the oncolytic bacteria. 29 to initiate accumulation. 25 Chemotactic response is triggered through specific receptor stimulation. Salmonella senses serine, aspartate, and ribose/galactose gradient, which guide it to tumors; moreover, inactivation of ribose/galactose receptor leads to the accumulation of bacteria in quiescent tumor areas. 27 These areas are ischemic, starved for nutrients, and therefore have limited responsiveness to chemotherapy. Modifications of bacterial capacity to react towards specific nutrients represent a strategy to direct Salmonella to specific quiescent tumor regions.
Modified bacteria in anticancer clinical studies Bacteria of the genus Salmonella, Shigella, and Listeria are potential vehicles for the delivery of therapeutic agents to human cells. Intracellular pathogens not only survive inside the cells but also reside there being capable of protein synthesis. The response against intracellular pathogens is polarized towards cellular response and can foster effective antitumor immunity. The toxicity of bacterial therapy can be controlled through the administration of antibiotics.
Preclinical results from murine tumor models encouraged human trials (TAbLE 2), and so far two modified intracellular bacteria have been safely administered to cancer patients: Listeria monocytogenes and S. typhimurium. L. monocytogenes attenuated strain CRS-207 (Cerus Corp., Concord, United States) is intended for the delivery FIGURE 1) . A suggested mode of action of the new therapeutic strain is presented in FIGURE 2. The antibody fragment is exposed on the surface of bacteria coupled to outer membrane protein OmpA, which is a member of the PAMP family able to induce dendritic cell maturation and activate natural killer cells through TLR-2 signaling. VNP20009 expressing anti-CEA scFv on the cell surface, administered by oral gavage, accumulated in the upper gastrointestinal tract of CEA transgenic mice and preferentially localized to CEA-expressing transplantable tumors after intravenous injection. Immunization with the modified bacteria led to substantial inhibition of tumor growth and more than doubled the survival time in an MC38CEA tumor transplantation model. Inhibition of tumor growth correlated with mobilization of CD3+ T cells and macrophages at the tumor site. Future perspectives are to define the effector immune cell populations associated with murine transplantable tumor growth control after administration of modified VNP20009. Toxicology studies of the modified strain on large mammals (pigs) and nonhuman primates are essential before proceeding to clinics. The optimization of scFv expression system will further improve therapeutic effectiveness, safety, and stability of the modification. Due to the modular character of the system, it can be adapted to target other tumors and to deliver various genes or gene products to augment immunity or deliver therapeutic agents to tumors. Our murine tumor model was based on CEA antigen expressed on cancer cells and CEA-specific antibody variable fragment on VNP20009 surface. The genetic modification is possible to equip bacteria with the antibody of other specificity in order to target a solid tumor expressing the relevant antigen.
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S. typhimurium VNP20009 was intended for the targeting of cancer through preferential accumulation in solid tumors, in order to deliver a therapeutic agent. The safety issues were addressed by modifications of the bacteria making it dependent on the external source of meta bolites and lowering the ability to induce septic shock. VNP20009 is a genetically modified strain with attenuated virulence and confirmed safety profile for intravenous administration in humans. It has been shown to preferentially colonize solid tumors in mice and dogs. 30, 31 In contrast to modified L. monocytogenes, VNP20009 load in the liver and spleen after systemic administration in tumor--bearing mice is around thousand times lower than in the solid tumor. The system for surface expression of heterologous proteins in gram-positive L. monocytogenes is not available at present, thus facilitation of targeting via tumor antigen binding is not possible.
Two major mutations in VNP20009 determine attenuation of the virulence. Mutation in purI gene results in purine deficiency and limited replication rate. The risk of lipopolysaccharide induced septic shock is limited due to partial deletion of msbB gene, which decreases the ability of lipopolysaccharide to stimulate TNF-α production. Phase I clinical trial conducted on 24 patients with advanced melanoma was not satisfactory regarding preferential localization of VNP20009 within the tumor lesion, observed in other mammals.
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Only 3 of 18 tumor bio psies contained viable bacteria and tumor growth regression was not observed. These studies, however, led to the conclusion that intravenous administration of large amounts of VNP20009 is well tolerated, which confirms the fact that VNP20009 is a safe vaccine vector and can be used in humans. A high proportion of bacteria accumulated in the tumor is necessary to boost the efficiency of immunotherapy and to minimize adverse effects.
To improve selective accumulation in solid tumors, we modified VNP20009 to express a single chain antibody fragment (scFv) specific for carcinoembryonic antigen (CEA) present on tumor cells. 33 Tumor-specific antigen is used 
